WO2010104307A3 - Pharmaceutical compositions for treating or preventing diseases caused by the translocation of gsk3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of gsk3 from the cell nucleus to the cytoplasm - Google Patents

Pharmaceutical compositions for treating or preventing diseases caused by the translocation of gsk3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of gsk3 from the cell nucleus to the cytoplasm Download PDF

Info

Publication number
WO2010104307A3
WO2010104307A3 PCT/KR2010/001446 KR2010001446W WO2010104307A3 WO 2010104307 A3 WO2010104307 A3 WO 2010104307A3 KR 2010001446 W KR2010001446 W KR 2010001446W WO 2010104307 A3 WO2010104307 A3 WO 2010104307A3
Authority
WO
WIPO (PCT)
Prior art keywords
gsk3
translocation
cytoplasm
cell nucleus
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/001446
Other languages
French (fr)
Korean (ko)
Other versions
WO2010104307A2 (en
Inventor
육종인
김현실
김남희
노경태
김수연
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinformatics & Molecular Design Research Center
MEDIGENTEK CO Ltd
Original Assignee
Bioinformatics & Molecular Design Research Center
MEDIGENTEK CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinformatics & Molecular Design Research Center, MEDIGENTEK CO Ltd filed Critical Bioinformatics & Molecular Design Research Center
Publication of WO2010104307A2 publication Critical patent/WO2010104307A2/en
Publication of WO2010104307A3 publication Critical patent/WO2010104307A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to pharmaceutical compositions for treating or preventing diseases caused by the translocation of GSK3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of GSK3 from the cell nucleus to the cytoplasm. More particularly, the present invention relates to pharmaceutical compositions for inhibiting the growth or the metastatis of cancer cells and pharmaceutical compositions for treating autoimmune diseases, containing novel compounds for inhibiting the translocation of GSK3 from the cell nucleus to the cytoplasm. The present invention provides compositions for inhibiting the outbreak and progression of diseases caused by a decrease in the concentration of GSK3 in the nucleus and the translocation of GSK from the cell nucleus to the cytoplasm. The compounds according to the present invention inhibit the nuclear export function of GSK3 performed by Axin, and increase the concentration of GSK3 in the nucleus, and can thus be valuably used in treating or preventing a variety of diseases caused by a decrease in the concentration of GSK3 in the nucleus.
PCT/KR2010/001446 2009-03-07 2010-03-08 Pharmaceutical compositions for treating or preventing diseases caused by the translocation of gsk3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of gsk3 from the cell nucleus to the cytoplasm Ceased WO2010104307A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0019533 2009-03-07
KR20090019533 2009-03-07

Publications (2)

Publication Number Publication Date
WO2010104307A2 WO2010104307A2 (en) 2010-09-16
WO2010104307A3 true WO2010104307A3 (en) 2011-01-27

Family

ID=42728928

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2010/001446 Ceased WO2010104307A2 (en) 2009-03-07 2010-03-08 Pharmaceutical compositions for treating or preventing diseases caused by the translocation of gsk3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of gsk3 from the cell nucleus to the cytoplasm
PCT/KR2010/001444 Ceased WO2010104306A2 (en) 2009-03-07 2010-03-08 Pharmaceutical compositions for treating or preventing diseases caused by the translocation of gsk3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of gsk3 from the cell nucleus to the cytoplasm

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001444 Ceased WO2010104306A2 (en) 2009-03-07 2010-03-08 Pharmaceutical compositions for treating or preventing diseases caused by the translocation of gsk3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of gsk3 from the cell nucleus to the cytoplasm

Country Status (2)

Country Link
KR (3) KR20100101054A (en)
WO (2) WO2010104307A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX353408B (en) 2010-04-22 2018-01-11 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds.
KR20120063283A (en) * 2010-12-07 2012-06-15 제일약품주식회사 Novel pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
CN106986869A (en) * 2012-04-17 2017-07-28 吉利德科学公司 Compounds and methods for for antiviral therapy
AU2014225992B2 (en) * 2013-03-06 2018-03-22 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
KR102223384B1 (en) * 2013-03-06 2021-03-05 알러간, 인코포레이티드 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
TW201522337A (en) 2013-03-12 2015-06-16 Arqule Inc Substituted tricyclic pyrazolo-pyrimidine compounds
PL3087051T3 (en) * 2013-12-24 2021-02-22 Oncotartis Inc. Benzamide and nicotinamide compounds and methods of using same
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
MX373103B (en) 2014-02-13 2020-04-17 Incyte Holdings Corp CYCLOPROPYLAMINES AS INHIBITORS OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1).
SI3105218T1 (en) 2014-02-13 2019-11-29 Incyte Corp Cyclopropylamines as lsd1 inhibitors
RU2744460C2 (en) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Pharmaceutical compositions for treating diseases mediated by cystic fibrosis transmembrane conductance regulator
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (en) 2014-07-10 2020-03-11 美商英塞特公司 Imidazopyridines and imidazopyrazines as LSD1 inhibitors
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
JO3637B1 (en) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
LT3334709T (en) 2015-08-12 2025-03-10 Incyte Holdings Corporation Salts of an lsd1 inhibitor
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (en) 2015-12-17 2022-07-06 Incyte Corp N-phenyl-pyridine-2-carboxamide derivatives and their use as modulators of the PD-1/PD-L1 protein/protein interaction
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3436461T2 (en) 2016-03-28 2024-05-31 Incyte Corp Pyrrolotriazine compounds as TAM inhibitors
JP6999574B2 (en) 2016-04-22 2022-01-18 インサイト・コーポレイション Preparation of LSD1 inhibitor
ES2906460T3 (en) 2016-05-06 2022-04-18 Incyte Corp Heterocyclic compounds as immunomodulators
ES2905980T3 (en) 2016-05-26 2022-04-12 Incyte Corp Heterocyclic compounds as immunomodulators
BR112018076534A2 (en) 2016-06-20 2019-04-02 Incyte Corporation heterocyclic compounds as immunomodulators
MA45669A (en) 2016-07-14 2019-05-22 Incyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
ES2941716T3 (en) 2016-08-29 2023-05-25 Incyte Corp Heterocyclic compounds as immunomodulators
UA125650C2 (en) 2016-09-09 2022-05-11 Інсайт Корпорейшн HPK1 REGULATORS BASED ON PYRAZOLOPYRIDINE DERIVATIVES AND THEIR APPLICATIONS FOR CANCER TREATMENT
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
TW201811799A (en) 2016-09-09 2018-04-01 美商英塞特公司 Pyrazolopyrimidine compounds and uses thereof
EP3558990B1 (en) 2016-12-22 2022-08-10 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
ES2899402T3 (en) 2016-12-22 2022-03-11 Incyte Corp Pyridine derivatives as immunomodulators
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
ES2874756T3 (en) 2016-12-22 2021-11-05 Incyte Corp Triazolo [1,5-A] pyridine derivatives as immunomodulators
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
HRP20250272T1 (en) 2017-10-19 2025-04-25 Teijin Pharma Limited DERIVATIVES OF BENZIMIDAZOLE AND THEIR USE
TW201932470A (en) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 Pyrazolopyrimidines having activity against RSV
CN111670189A (en) 2018-01-31 2020-09-15 爱尔兰詹森科学公司 Cycloalkyl-substituted pyrazolopyrimidines having activity on RSV
US10800761B2 (en) 2018-02-20 2020-10-13 Incyte Corporation Carboxamide compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
BR122023024273A2 (en) 2018-02-27 2024-02-20 Incyte Corporation IMIDAZOPIRIMIDINE AND TRIAZOLOPYRIMIDIINE COMPOUNDS, THEIR USES, METHOD FOR INHIBITING AN ADENOSINE RECEPTOR ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF
CR20200520A (en) 2018-03-30 2021-03-09 Incyte Corp Heterocyclic compounds as immunomodulators
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
MA52348A (en) 2018-04-23 2021-03-03 Janssen Sciences Ireland Unlimited Co HETEROAROMATIC COMPOUNDS WITH AN ACTIVITY AGAINST RSV
WO2019217821A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
ES2973117T3 (en) 2018-09-25 2024-06-18 Incyte Corp Pyrazolo[4,3-d]pyrimidine compounds as modulators of ALK2 and/or FGFR
CN112969700B (en) 2018-10-30 2024-08-20 吉利德科学公司 Imidazolopyridine derivatives as α4β7 integrin inhibitors
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
KR102659859B1 (en) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 Compounds for inhibition of alpha4β7 integrin
ES2974634T3 (en) 2018-12-21 2024-06-28 Celgene Corp Thienopyridine inhibitors of RIPK2
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
MX2022001562A (en) 2019-08-06 2022-04-26 Incyte Corp SOLID FORMS OF AN INHIBITOR OF HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1).
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
KR102908219B1 (en) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 Compounds that inhibit alpha 4 beta 7 integrins
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (en) 2019-11-11 2022-10-11 Incyte Corp SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010052137A1 (en) * 2000-03-01 2001-12-13 Trustees Of The University Of Pennsylvania Axin domain-like polypeptide inhibitors of glycogen synthase kinase 3 beta activity and activators of wnt signaling
KR20050032105A (en) * 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Pyrazole compositions useful as inhibitors of gsk-3
US20070032474A1 (en) * 2003-06-10 2007-02-08 Biondi Ricardo M Use of a compound of formula 1 for making a pharmaceutical composition
KR20080038047A (en) * 2006-10-27 2008-05-02 김정문 Methods and Substances That Inhibit Uss3 Migration from Cell Nucleus to Cytoplasm
US20080161251A1 (en) * 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010052137A1 (en) * 2000-03-01 2001-12-13 Trustees Of The University Of Pennsylvania Axin domain-like polypeptide inhibitors of glycogen synthase kinase 3 beta activity and activators of wnt signaling
KR20050032105A (en) * 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Pyrazole compositions useful as inhibitors of gsk-3
US20070032474A1 (en) * 2003-06-10 2007-02-08 Biondi Ricardo M Use of a compound of formula 1 for making a pharmaceutical composition
US20080161251A1 (en) * 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
KR20080038047A (en) * 2006-10-27 2008-05-02 김정문 Methods and Substances That Inhibit Uss3 Migration from Cell Nucleus to Cytoplasm

Also Published As

Publication number Publication date
KR20100101056A (en) 2010-09-16
KR20100101055A (en) 2010-09-16
WO2010104306A3 (en) 2010-12-16
WO2010104306A2 (en) 2010-09-16
WO2010104307A2 (en) 2010-09-16
KR20100101054A (en) 2010-09-16

Similar Documents

Publication Publication Date Title
WO2010104307A3 (en) Pharmaceutical compositions for treating or preventing diseases caused by the translocation of gsk3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of gsk3 from the cell nucleus to the cytoplasm
WO2011111880A9 (en) Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
MY170912A (en) Compositions comprising c6 oligosaccharides
MX2012004210A (en) Pyrazole derivatives as modulators of calcium release -activated calcium channel.
WO2010101964A3 (en) Methods and compositions useful in treating cancer and reducing wnt mediated effects in a cell
WO2011085263A3 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
WO2011056021A3 (en) Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis
WO2013093508A3 (en) Wnt pathway inhibitors
WO2009070244A3 (en) Methods for inhibiting fascin
WO2011160021A3 (en) Fullerene derivatives and photovoltaic cell containing them
PH12014501032A1 (en) 2-thiopyrimidinones
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
WO2013034989A3 (en) Microrna-based methods and assays for osteosarcoma
EA201391360A1 (en) PREVENTION OR REDUCTION OF SCRAPS IN THE MANUFACTURE OF EXTRACTIONPHOSPHIC ACID
WO2011150457A3 (en) Haematopoietic-prostaglandin d2 synthase inhibitors
WO2011115810A3 (en) Isoform-specific rnai based on codon redundancy/degeneracy
WO2012071562A3 (en) Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compound
WO2012112156A3 (en) Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof
SG195170A1 (en) Methods of treating or preventing rheumatic disease
MX2013012648A (en) Method for determining clinically relevant hypoxia in cancer.
WO2011150229A3 (en) Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10750998

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10750998

Country of ref document: EP

Kind code of ref document: A2